<DOC>
	<DOCNO>NCT02016170</DOCNO>
	<brief_summary>Recently , two new oral P2Y12 antagonists approve clinical use : prasugrel , third generation thienopyridine , ticagrelor , first class cyclopentyltriazolopyrimidine ( CPTP ) . These agent show associated potent platelet inhibitory effect compare clopidogrel . In addition , agent show superior clopidogrel prevent recurrent ischemic event set acute coronary syndrome ( ACS ) . Understanding switch patient prasugrel ticagrelor unmet need clinical interest . The propose PD investigation prospective , randomize , parallel design aim show switch patient prasugrel ticagrelor provide similar level platelet inhibition .</brief_summary>
	<brief_title>Pharmacodynamic Evaluation Switching From Prasugrel Ticagrelor</brief_title>
	<detailed_description>Dual antiplatelet therapy consist aspirin P2Y12 receptor antagonist cornerstone treatment secondary prevention thrombotic event patient coronary artery disease . Recently , two new oral P2Y12 antagonists approve clinical use : prasugrel , third generation thienopyridine , ticagrelor , first class cyclopentyltriazolopyrimidine ( CPTP ) . These agent show associated potent platelet inhibitory effect compare clopidogrel . In addition , agent show superior clopidogrel prevent recurrent ischemic event set acute coronary syndrome ( ACS ) . Therefore , current guideline recommend prasugrel ticagrelor ( first line therapy accord European Society Cardiology ) ACS patient undergo percutaneous coronary intervention ( PCI ) . Despite broad indication ticagrelor ( also medically manage ACS ) mortality benefit , prasugrel high uptake ticagrelor US market , likely due earlier approval . Further , implementation prasugrel institutional protocol , particularly ST elevation myocardial infarction ( STEMI ) patient undergo primary PCI , may also reason slow uptake ticagrelor . However , many clinician would indeed consider ticagrelor long-term treatment choice variety reason . Therefore , understand switch patient prasugrel ticagrelor unmet need clinical interest . However , currently , data pharmacodynamic ( PD ) effect switch prasugrel ticagrelor . The propose PD investigation prospective , randomize , parallel design aim show switch patient prasugrel ticagrelor provide similar level platelet inhibition . This study provide insight PD effect switch help clinician choose appropriate schema avoid complication related inadequate antiplatelet therapy patient coronary artery disease switch prasugrel ticagrelor desire .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Prasugrel Hydrochloride</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<mesh_term>Adenosine</mesh_term>
	<criteria>Patients know coronary artery disease present ACS underwent PCI . Age 18 74 year old . On therapy lowdose aspirin ( 81 mg ) prasugrel 10 mg/daily least 14 day per standard care Exclusion criterion : History stroke , transient ischemic attack ( TIA ) intracranial bleeding . Known allergy ticagrelor . Weight &lt; 60 Kg On treatment oral anticoagulant ( Vitamin K antagonist , dabigatran , rivaroxaban ) . Treatment IIb/IIIa glycoprotein inhibitor last 7 day . Blood dyscrasia bleed diathesis . Platelet count &lt; 80x106/mL . Hemoglobin &lt; 10 g/dL . Active bleeding . Hemodynamic instability . Creatinine Clearance &lt; 30 mL/minute . Known severe hepatic dysfunction . Patients sick sinus syndrome ( SSS ) high degree atrioventricular block without pacemaker protection . Current treatment drug interfere cytochrom P450 3A4 metabolism ( avoid interaction Ticagrelor ) : Ketoconazole , itraconazole , voriconazole , clarithromycin , nefazodone , ritonavir , saquinavir , nelfinavir , indinavir , atazanavir , telithromycin . Pregnant female .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>platelet reactivity</keyword>
	<keyword>ticagrelor</keyword>
	<keyword>prasugrel</keyword>
</DOC>